Rheumatology News

The AMA House of Delegates adopted several new policies to promote public health at its annual meeting.

Nearly half of patients with gout achieved remission with pegloticase treatment by 52 weeks, indicating longer-term benefits for intensive urate-lowering therapy, according to data presented at EULAR 2024 Congress.

Patients with lupus nephritis who receive higher initial doses of glucocorticoids demonstrate improved renal outcomes, albeit with increased serious infection and mortality risks, according to data published in Arthritis & Rheumatology.

The AMA adopted policies to protect patients’ access to necessary health care in a variety of ways at its annual meeting.

A new trial center network and two major data collection projects are among recent EULAR initiatives for improved care of patients with rheumatic and musculoskeletal diseases, according to a speaker at the EULAR 2024 Congress.

Treatment with belimumab resulted in fewer flares in patients with either early or established systemic lupus erythematosus, especially among those with no baseline organ damage, according to data presented at the EULAR 2024 Congress.

The AMA adopted new policies on broader Medicare and Medicaid health care coverage during its annual House of Delegates meeting.

The AMA announced a new policy that supports requirements for drug and device sponsors to develop diversity action plans so that women and sexual and gender minorities are adequately represented in their clinical trials.

Difficult-to-treat psoriatic arthritis was common in a large, real-life cohort, with key risk factors including extensive psoriasis, higher BMI and a history of inflammatory bowel disease, according to data published in Rheumatology.

The AMA House of Delegates adopted two new policies aiming to reform prior authorization and the burden it causes patients and physicians.